S
SAB Biotherapeutics
A clinical-stage biopharmaceutical development company
About SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm that develops fully human polyclonal immunotherapeutic antibodies to address immunology disorders and infectious diseases. Founded in 2014 by Eddie J. Sullivan, Christine Hamilton, and Edward Hamilton, the company emerged from the 2014 merger of Sanford Applied Bioscience and BioDak. Dr. Sullivan, who has over 25 years of experience in biopharma leadership, currently serves as President, while Samuel J. Reich assumed the role of CEO in early 2024. The founders' journey is deeply connected to their background in large animal veterinary medicine and ranching, which provided the foundation for the company's core technology.
The company's core asset is its proprietary DiversitAb™ platform, which utilizes genetically engineered transchromosomic (Tc) cattle to produce targeted, high-potency, fully-human polyclonal antibodies without requiring human donors. This technology enables the rapid development of antibody therapeutics, with the potential to move a candidate from concept to clinic in under five months. SAB operates through a single segment focused on developing these therapies, with its headquarters and manufacturing facilities located in Sioux Falls, South Dakota.
SAB Biotherapeutics' business model is centered on advancing its pipeline of drug candidates through clinical trials to gain regulatory approval and eventual commercialization. Its revenue has historically been generated from government contracts and grants, including significant funding from the U.S. Department of Defense and BARDA for programs related to COVID-19 and influenza. For the fiscal year 2024, the company reported revenues of $1.32 million. A significant milestone was achieved in October 2021 when SAB became a publicly traded company on the Nasdaq (ticker: SABS) through a merger with Big Cypress Acquisition Corp., a special purpose acquisition company (SPAC). This transaction provided approximately $118 million in cash resources to fuel the development of its platform and pipeline.
The company's lead product candidate is SAB-142, a fully human anti-thymocyte globulin (hIgG) intended to delay the onset and progression of Type 1 Diabetes (T1D). SAB-142 has demonstrated a favorable safety profile in Phase 1 trials and is advancing toward a Phase 2b study. Other notable pipeline programs include SAB-176 for severe influenza, which has been granted Breakthrough Therapy and Fast Track designations by the FDA, and SAB-195 for Clostridioides difficile (C. diff) infection. The company serves a global market, targeting diseases with significant unmet medical needs, and collaborates with government agencies, academic institutions, and pharmaceutical companies to advance its research.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 90
- Open positions
- None listed
- Dealroom signal
- 91.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, SPAC Target, SPAC IPO Announced, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $85M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2025 | $175M | — | Blackstone · JDRF T1D Fund · Vivo Capital · ATW Partners | ↗ |
Growth signals
Latest recorded traffic for SAB Biotherapeutics is 11K monthly website visits, up 71.9% over the last three months. SAB Biotherapeutics's team grew 30.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SAB Biotherapeutics in the Miami Beach ecosystem
The SAB Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
HHS Administration for Strategic Preparedness and Response
Series A2 investors entered at this stage
Siouxfallsdevelopment
Merck & Co.
Series B and later2 investors entered at this stage
Big Cypress Acquisition
US Department of War
Other known investors15 additional known investors
Commodore Capital
JDRF T1D Fund
RA Capital Management- SCSessa Capital
ATW Partners
Blackstone
BVF Partners
Forge Life Science Partners
Marshall Wace
RTW Investments
Sanofi
Spruce Street Capital
University of Massachusetts Amherst
Vivo Capital
Woodline Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SAB Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SAB Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










